Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group - Test2 - elhamkhani - TriplyDB

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

http://www.wikidata.org/entity/Q33503725

about

Temozolomide for children and adolescents with diffuse intrinsic pontine glioma In vitro drug response and efflux transporters associated with drug resistance in pediatric high grade glioma and diffuse intrinsic pontine glioma Advances in the management of paediatric high-grade glioma.Temozolomide in paediatric high-grade glioma: a key for combination therapy?Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).Temozolomide in resistant or relapsed pediatric solid tumors.Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.Phase II trial of temozolomide in children with recurrent high-grade glioma.Temozolomide: a milestone in neuro-oncology and beyond?Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan.Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide Clinical management of brain stem glioma Novel chemotherapeutic agents for the treatment of brain cancer.Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma.Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program Role of temozolomide in pediatric brain tumors.State of the art chemotherapeutic management of pediatric brain tumors.Treatments for astrocytic tumors in children: current and emerging strategies.Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.Treatment of paediatric pontine glioma with oral trophosphamide and etoposide Pediatric CNS tumors: current treatment and future directions.Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.Pediatric brain tumors: current treatment strategies and future therapeutic approaches Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.Outcome of young children with high-grade glioma treated with irradiation-avoiding intensive chemotherapy regimens: Final report of the Head Start II and III trials.Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines.Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database.MGMT gene promoter methylation in pediatric glioblastomas.Temozolomide in relapsed pediatric brain tumors: 14 cases from a single center.Proceedings of the diffuse intrinsic pontine glioma (DIPG) Toronto Think Tank: advancing basic and translational research and cooperation in DIPG.Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors.A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma.

P2860

Q24200164-23C7EC89-732C-46A8-AC5B-B0E1E2652DDF Q28487205-9AA04CD8-E0A5-41C8-9131-49A7E557DD13 Q30870633-F92EBF0C-071A-463F-9A89-A9EE0DEA5C99 Q33361765-F5179FCF-FD54-4407-91DA-ED7E99B4EC29 Q33363847-25DC8EAA-D8DE-4D16-A86C-FE083AEBC830 Q33367496-0CF1ABC2-FC78-48D8-ABDA-B88A10E0E204 Q33368246-333E1353-922F-4601-AC65-90FFCC1BA02E Q33369255-8B38CBF3-B387-4EAA-9B91-41D08B532060 Q33372340-96C998A3-CAA8-4FE7-80A0-607CC338225E Q33376286-BF5E5B77-D469-41B2-953E-8BADB9204076 Q33377664-32B6C908-35C4-4058-A2F8-11E563C18880 Q33392673-4BCD5917-61D0-4ABE-B0D8-BE1AC1992393 Q33413067-20A11D56-0511-4BC9-AA9E-9DC77905194D Q33566420-385B209A-4306-47F4-9871-A36CBCBF6291 Q33637352-2E916736-5A02-4C8C-B15B-7F62CBF04F63 Q34090967-58C43F10-B9B5-492D-B204-ECD8C48C2CE0 Q34418437-C2CBB46C-1307-4EFD-94E0-76003BF12DC8 Q34481867-F6E00AFF-8538-494E-A5A8-E243198BA11C Q34571940-CD1283C0-C70B-41A0-8913-6402C6E08EE3 Q36432438-1BF1F682-3DEA-4107-BD31-AC51F1B68482 Q36492376-2D4158E2-2598-47D2-9E26-1763D2BF3416 Q36506770-7E5A0C3E-3287-46D4-A33A-B3BE17665EB8 Q36616482-FE19C8A1-C810-4301-BC69-444EC00FFB21 Q36624343-A40D89F7-37E9-4534-9D84-A1AD9F119466 Q36902043-98CF1A7F-0AF2-4000-8F4F-94CB3D018A23 Q37454341-B0E408F6-0CC3-4E1E-9956-F57FBB3F1C5E Q37533670-B2375FBC-186C-4060-AAA2-50D867E5F11F Q37564201-BCC0E40E-4E11-4840-88B4-FAF5581E264C Q38086448-01B4DAA7-6001-4939-9FF5-3C56A36DAF56 Q38873292-FEE55B0B-9103-4082-981D-CA6F7DC3FF3D Q38891614-11000F41-08B4-40F3-B6D7-B9695196BE52 Q38961012-CC78E141-A6D2-46BF-AFC4-70CC161CFFFA Q39208269-85C3BAC1-356F-42C9-B570-74F61C17F62F Q39874006-43868EB6-540C-4CE7-AA2C-5C98092B7E6A Q42523871-6645240F-64D0-404D-B1C2-3F3BA8B38F20 Q43002702-7862AC43-2204-4DC6-ABEC-8315EF459C07 Q44596535-00242217-834E-442D-A395-4ACF8FDFEA60 Q45384951-1E4CE1D9-10FC-4467-800F-3A551544344C Q46017033-7A706C79-4379-481E-8AED-AFBD1D061620 Q46188537-B1C181C5-FBAA-4FC1-A6F8-B1B44046F4B9

P2860

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

http://www.wikidata.org/entity/Q33503725

description

1998 nî lūn-bûn

@nan

1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1998年の論文

@ja

1998年論文

@yue

1998年論文

@zh-hant

1998年論文

@zh-hk

1998年論文

@zh-mo

1998年論文

@zh-tw

1998年论文

@wuu

name

Phase I study of temozolomide ...... Children's Cancer Study Group

@ast

Phase I study of temozolomide ...... Children's Cancer Study Group

@en

type

label

Phase I study of temozolomide ...... Children's Cancer Study Group

@ast

Phase I study of temozolomide ...... Children's Cancer Study Group

@en

prefLabel

Phase I study of temozolomide ...... Children's Cancer Study Group

@ast

Phase I study of temozolomide ...... Children's Cancer Study Group

@en

P1433

Q33503725-066CDA00-B216-4741-B735-ACF673A83BDB

P1476

Q33503725-6EDB5756-ADAC-44E5-9990-9F2FF83FA3FD

P2093

Q33503725-173CCA5E-5A75-4C96-B3EC-EFBBFD043C0D

Q33503725-1C2C0D90-F736-458C-88DC-2DB13203C527

Q33503725-2B1AA9C6-AD7F-432C-B198-73DBBAD1F503

Q33503725-3A44822C-F6CA-42CC-B350-F79ACFCAF447

Q33503725-4B05AB6D-2713-4005-A5CE-9354457D5101

Q33503725-561B41CA-8149-408B-A0D6-940FCF8FF157

Q33503725-6BA56362-3EBE-4B39-AA24-BB0A2231DB8A

Q33503725-6E5980C1-9C56-419D-805E-33432AF6B8B6

Q33503725-85D28384-8422-42D5-B841-278317851678

Q33503725-9FBF6CA0-7348-45BF-B947-595F12BD2062

P2860

Q33503725-068249D7-B141-4DCB-AB48-9990C85726F2

Q33503725-227892AF-2495-4B30-BAAC-178E855857DA

Q33503725-24E837A7-269D-4D96-A80C-5D27EEEC7E7A

Q33503725-2592700C-56E4-4AE6-A3D3-05E9AC09EF23

Q33503725-2A48235D-21FD-456B-84E5-F4BF9851F1D3

Q33503725-4377CFDA-7B48-4938-B4FC-54C46D766F56

Q33503725-444B47C0-F7E6-48D4-87CA-617FEC7D1028

Q33503725-5902624F-3C29-4276-8A43-6BB5FE4F9E55

Q33503725-8A3F8287-F1CB-49A8-85B7-3F44DF29671C

Q33503725-C394695B-095E-4055-91D7-1BDE83CD4EB3

P2888

Q33503725-178EF410-2B36-4059-87B1-8F791474BCA6

P304

Q33503725-4EE470FE-5E6F-4841-9454-6FFD643929BE

P31

Q33503725-ED32BE8D-1EDF-4CBF-AA10-4DA6413408DD

P356

Q33503725-B9B9D13A-33A8-45F1-89D3-DEBB78223CE9

P407

Q33503725-FC9330F2-C94C-4624-A997-A0A156F72485

P433

Q33503725-D1B579F9-64D0-4C8C-8A4F-045446CEDCC5

P478

Q33503725-49401355-F97D-44F2-8F8A-8E44D64EC562

P577

Q33503725-D18DC6C2-25DA-43E7-BEB5-1AFB58E332AC

P5875

Q33503725-5061656E-C41D-42EC-A0F1-1710D64FB283

P6179

Q33503725-AB9A4A02-ECF7-46BB-B38B-C6F3E8EEEBBF

P698

Q33503725-5913C78A-1CCB-4144-AF43-632F7D23594E

P932

Q33503725-73040CDF-FE18-4577-BAAB-719C09BD30C4

P356

P1433

British Journal of Cancer

P1476

Phase I study of temozolomide ...... Children's Cancer Study Group

@en

P2093

A D Pearson

http://www.w3.org/2001/XMLSchema#string

A Gholkar

http://www.w3.org/2001/XMLSchema#string

A Marco

http://www.w3.org/2001/XMLSchema#string

B Morland

http://www.w3.org/2001/XMLSchema#string

C Dicks-Mireaux

http://www.w3.org/2001/XMLSchema#string

C R Pinkerton

http://www.w3.org/2001/XMLSchema#string

D R Newell

http://www.w3.org/2001/XMLSchema#string

D Walker

http://www.w3.org/2001/XMLSchema#string

E J Estlin

http://www.w3.org/2001/XMLSchema#string

H McDowell

http://www.w3.org/2001/XMLSchema#string

P2860

Phase I trial of temozolomide (CCRG 81045: M&B; 39831: NSC 362856)

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma.

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer.

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine.

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary.

A comparison of two phase I trial designs.

P2888

P304

652-661

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1998.555

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

78

http://www.w3.org/2001/XMLSchema#string

P577

1998-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

253934500

http://www.w3.org/2001/XMLSchema#string

P6179

1014948420

http://www.w3.org/2001/XMLSchema#string

P698

9744506

http://www.w3.org/2001/XMLSchema#string

P932

2063055

http://www.w3.org/2001/XMLSchema#string